The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Prophylactic cyclophosphamide for delayed neurotoxicity after cilta-cel in multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses prophylactic cyclophosphamide for patients with multiple myeloma at increased risk of delayed neurotoxicity following ciltacabtagene autoleucel (cilta-cel) therapy. She highlights findings showing no reduction in the incidence of Parkinsonism among patients with high lymphocyte expansion, but suggests that symptoms may be less severe with cyclophosphamide prophylaxis. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
